By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Editas Medicine 

300 Third Street, First Floor

Cambridge  Massachusetts  02142  U.S.A.
Phone: 617-401-9000 Fax: n/a


SEARCH JOBS

Editas Medicine is a transformative genome editing company founded by world leaders in the fields of genome editing, protein engineering, and molecular and structural biology, with specific expertise in CRISPR/Cas9 and TALENs technologies.

The company's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products.

Editas was founded in 2013 with $43 million in Series A venture capital financing led by leading health care venture capital firms Flagship Ventures, Polaris Partners and Third Rock Ventures with participation from Partners Innovation Fund.


YEAR FOUNDED:

2013

LEADERSHIP:

Founders: Feng Zhang, Jennifer Doudna, George Church, J. Keith Joung, and David Liu

CEO: Karine Bosley

CFO: Andrew Hack

COO: Alexandra Glucksmann

CTO: Vic Myer

JOBS:

Please click here for Editas Medicine job opportunities.

FOLLOW EDITAS MEDICINE:



Key Statistics


Email: dan@purecommunicationsinc.com
Ownership: Public

Web Site: Editas Medicine
Employees: n/a
Symbol: EDIT
 



Industry
Biotechnology

Segment
Genomics
Start Up





Company News
Is Editas Medicine (EDIT) Facing A New Reality In CRISPR Land? 5/17/2017 6:13:46 AM
Editas Medicine (EDIT) Delays IND for Lead CRISPR Candidate 5/16/2017 11:24:35 AM
Editas Medicine (EDIT) Demonstrates First Achievement Of In Vivo Editing In Non-Human Primate Retinas 5/15/2017 10:29:07 AM
Editas Medicine (EDIT) Announces Pre-Clinical Data For Program To Treat Sickle Cell Disease And Beta-Thalassemia 5/11/2017 8:41:38 AM
Editas Medicine (EDIT) To Host Conference Call Discussing First Quarter 2017 Corporate Update And Results 5/9/2017 10:55:15 AM
Editas Medicine (EDIT), Veritas Genetics Co-Founder and Biotech Phenom George Church Makes Time's 100 'Most Influential' List 4/21/2017 5:51:07 AM
Turns Out Editas Medicine (EDIT)'s R&D Deal With Allergan (AGN) Could be Worth $1 Billion 3/23/2017 6:03:11 AM
Third Rock Ventures Quietly Launches Tango Therapeutics in Editas Medicine (EDIT)’s HQ 3/7/2017 6:11:22 AM
COO and First Employee of Editas Medicine (EDIT) to Exit, Effective March 31 3/6/2017 5:32:02 AM
Editas Medicine (EDIT) to Pay Six Academic Centers for Exclusive Rights to a New System That Might Improve CRISPR-Cas9 12/20/2016 6:51:40 AM
12345
//-->